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Abstract
Diffuse large B-cell lymphoma (DLBCL) is a potentially curable disease, but standard treatment is not effective enough for 
all patients. That is why so important to identify high risk patients who need more aggressive therapy at the time of diagnosis. Now-
adays prognosis for patients with DLBCL is based on International prognostic index (IPI). However, this index consists of only clin-
ical parameters and does not include the biological characteristics of the tumour. Immunohistochemistry (IHC) markers could also 
play a prognostic role. There are some publications regarding predictive and prognostic role of expression of Bcl-2, Bcl-6, MUM1, 
CD10 and CD30, but their results are controversial. The aim of our study was to analyze prognostic role of these markers, to compare 
survival of patients with positive and negative expression of these markers and to build a prognostic model which include biological 
parameters for identifying high risk patients. There were statistically significant differences in EFS between the group of patients 
with negative and positive expression of CD10 (51.5 % versus 72.5 %, р=0.01) and in OS between the group of patients with negative 
and positive expression of Bcl-6 (61.1 % versus 79.6 %, р=0.03). Six-factors nonlinear neural network prediction model (MLP_6) was 
built. The sensitivity of the model is 63.2 % (95 % CІ 49.3 % – 75.6 %), specificity – 85.2 % (95 % CІ 79.1 % – 90.1 %). Prognostic 
factors include negative IHC expression of Bcl-6, CD10, non-GCB molecular subtype (according to algorithm Hans), gender (male), 
advanced Ann-Arbor stages, >2 extranodal involvement. Our nonlinear neural network prediction model could improve prognostic 
role of IPI by adding of biological tumour characteristics (IHC expression of CD10, Bcl-6, molecular subtype by IHC algorithm).
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1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is a potentially curable disease, but unfortunately 
approximately 40 % of patients are refractory to the primary therapy or develop relapse after first 
line therapy [1, 2].
Standard of treatment is not effective enough for this group of patients. That is why so im-
portant to identify high risk patients who need more aggressive therapy at the time of diagnosis. 
On the other hand there are a lot of new drugs recently and searching for prognostic markers is 
extremely important for risk stratification of patients in order to individualize treatment. 
Nowadays prognosis for patients with DLBCL is based on International prognostic index 
(IPI) [3]. IPI was described in1993 based on the analysis of 3273 patients with aggressive non-Hod-
gkin lymphoma in1 6 Oncologic centers, received CHOP-like treatment. Based on such negative 
prognostic factors as age more than 60 years old, elevated lactate dehydrohynase, status ECOG>1, 
ІІІ–ІV stages, extranodal sites of involvement >1, patients were divided into four risk groups: low 
(0–1 factor), low-intermediate (2 factors), high-intermediate (3 factors) and high risk (4–5 factors) 
with 5-year overall survival (OS) 73 %, 51 %, 43 % і 26 % accordingly [3]. However, despite its 
wide spread use in clinical practice and predictive value, this index consists of only clinical pa-
rameters and does not include the biological characteristics of the tumour. Immunohistochemistry 
(IHC) markers which are used for diagnosis of lymphoma and play important role in its pathogene-
sis could also play a prognostic role. There are some publications regarding predictive and prognos-
tic role of expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30, but their results are controversial.
Positive expression of MUM1 is associated with inferior outcome according to the several 
study results [4, 5]. And some study results demonstrated positive prognosis in case of positive 
expression of this marker [6, 7].
According to the results of Berglund and Sjöetal positive expression of CD10 is a positive 
prognostic factor [8, 9] and have no prognostic impact according other results [10].
Negative prognostic influence of Bcl-2 was demonstrated in several studies [8, 11]. And 
according to other results there is no prognostic value of this marker [12, 13].Negative Bcl-6 ex-
pression is associated with inferior survival according Horn and his colleagues [14, 15] and there is 
no prognostic value of this marker according others results [16].
2. Aim of research
The aim of the study was to identify the prognostic role of immunohistochemical markers 
and to find prognostic model for detecting patients with survival less than 12 months. 
3. Materials and methods
In the retrospective analysis were included 349 patients with newly diagnosed DLBCL 
who were treated at the National Cancer Institute (Kyiv, Ukraine) from December, 2014 to De-
cember, 2017. IHC expression of Bcl-2, Bcl-6, MUM1, C-MYC, CD10 or CD30 in these patients 
were compared. 
IPI factors and survival between groups of patients with positive and negative expression of 
IHC markers were compared. For identifying of molecular subtype (germinal center (GCB) DLBCL 
or non-germinal center DLBCL (non-GCB)) immunohistochemical Hans algorithm was used [17].
Group comparisons were performed by means of χ2 and Student’s t tests. For time to event 
analyses we used EZR v. 1.35 (Saitama Medical Center, Jichi Medical University, Saitama, Japan, 
2017), applying Kaplan-Meier survival estimates with the end-point of overall survival, defined as 
the time from initial diagnosis to death from any cause [18]. P values less than 0.05 were considered 
statistically significant.
For the analysis of the risk of death in the first 12 months after diagnosis and construction 
of the system for predicting this risk, the method of analysis of neural network models [19] was 
used. To select a minimum set of parameters related to the risk of early death, the method of genetic 
algorithm for selecting variables [19] was used.
In order to assess the adequacy of the forecasting model, the method of constructing and an-
alyzing the operational characteristics curves of the models (ROC curves) was used, the estimation 
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of the quality of the prediction was made by assessing of area under the operational characteristics 
curve (AUC), sensitivity, specificity, predictability of the positive result, and the prediction of the 
negative outcome, the corresponding 95 % of the indicators were calculated [20].
4. Result
There were 162 (46.4 %) men and 187 (53.6 %) women. Age of patients was from 17 to 
86 years, median age – 54.0±1.1 years of old (95 % CI 50-56). Early stages (І–ІІ) were registered 
in 182 (52.1 %) of patients, advanced stages (ІІІ–ІV) – in 167 (47.9 %). There were В-symptoms in 
127 (36.4 %) of patients. There was low and low-intermediate IPI in 238 (68.2 %) of patients and 
111 (31.8 %) high and high-intermediate risk patients. There were 132 (37.8 %) patients older than 
60 years old, 153 (43.8 %) patients with elevated LDH, 167 (47.9 %) patients with advanced stages, 
89 (25.5 %) patients with ECOG >2 and 99 (28.4 %) patients with more than two extranodal sites of 
involvement. Rituximab-based chemotherapy received 186 of patients (53.3 %), patients received 
1-8 courses of chemotherapy (6±0.1 courses, 95 % CI 5.0–7.0). Radiation therapy received 116 of 
patients (33.2 %). Median follow up was 12.7 months.
Positive expression of Bcl-2, Bcl-6, MUM1, C-MYC, CD10 or CD30 was registered in 
79.4 %, 56.8 %, 63.7 %, 28 %, 38.2 %, and 23.5 % accordingly (Fig. 1).
Fig. 1. Incidence of positive (blue color) and negative (red color) expression of IHC markers
In the Table 1 IPI factors distribution depending on positive or negative expression of IHC 
markers is demonstrated. 
Table 1
IPI risk factors in the group with positive and negative expression of IHC markers
% IHC Age>60 Stage ІІІ-IV >2 extranodal sites LDN>N ECOG>2 IPI 3-5
1 2 3 4 5 6 7
Bcl-2+ 42 53.5 32 55.3 28 38
Bcl-2- 28.8 35 23 63.6 23 21
p 0.12 0.08 0,27 0.41 0.69 0.04
Bcl-6+ 33.3 45.8 31,9 59 25.4 34.2
Bcl-6- 39.5 56 32,9 63,4 31.8 35.1
p 0.43 0,18 0.99 0.68 0.38 0.99
MUM1+ 41.5 44.5 24.4 55.8 24.4 32.3
MUM1- 35.1 44.5 31.1 52.2 22.9 28.3
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1 2 3 4 5 6 7
p 0.45 0.7 0.67 0.76 0.95 1.0
CD10+ 30.9 38 27.4 51.3 22.6 27.4
CD10- 42.6 51.4 30.4 55 25 33.8
p 0.11 0.053 0.75 0.74 0.82 0.39
CD30+ 25.9 44.4 33.3 54.5 22.2 18.5
CD30- 38.6 54.4 26.4 50 27.7 31.8
p 0.32 0.48 0.97 0.89 0.91 0.27
C-MYC + 37.1 57.1 37.1 51.5 40 42.8
C-MYC – 44.4 54.4 38.2 72.7 32.5 50
p 0.59 0.08 0.95 0.053 0.57 0.6
There were no difference in age> 60 years old, advanced stages, elevated LDH, more than 
two extranodal involvements, ECOG>2 between patients with positive and negative expression 
of Bcl-2, Bcl-6, CD10, CD30, MUM1 та C-MYC. There was similar distribution of high risk pa-
tient between with positive and negative expression of Bcl-6, CD10, CD30, MUM1 та C-MYC. 
There were more high risk patients according IPI in the group of patients with positive Bcl-2 
expression (р=0.04).
Two-year overall survival (OS) and event-free survival (EFS) were analyzed and compared 
between group of patients with positive and negative expression of IHC markers (Table 2).
Table 2
Two-year overall and event-free survival in patients with positive and negative expression of IHC markers
IHC, % EFS, % 95 % CІ OS, % 95 % CІ
Bcl-2+ 65.5±7.35 49.1–77.8 73.23.8± 64.8–79.8
Bcl-2– 61.44.1± 52.9–68.9 76.36.7± 59.9–86.6
p 0.6 0.8
Bcl-6+ 52.96.36± 39.8–64.4 79.64.3± 69.5–86.6
Bcl-6– 63.25.17± 52.2–72.4 61.16.3± 47.6–72.1
p 0.2 0.03
MUM1+ 63.04.86± 52.7–71.7 77.04.9± 65.5–85.1
MUM1– 57.07.21± 41.8–69.7 66.76.8± 51.5–78.1
p 0.7 0.1
CD10+ 72.55.58± 59.8–81.7 77.05.8± 62.9–86.3
CD10– 51.55.38± 42.7–63.0 68.35± 57.1–77.1
p 0.01 0.2
CD30+ 53.111.1± 29.9–71.8 65.410.9± 39.9–82.2
CD30- 54.66.6± 40.8–66.4 68.66.4± 54.1–79.3
p 0.9 0.805
MYC+ 47.912.85± 22.2–69.7 67.514.3± 32.2–87.3
MYC– 59.46.03± 46.6–70.0 69.06.15± 55.2–79.3
p 0.9 0.5
Continuation of Table 1
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In the group of patients with negative expression of CD10 there EFS was worse comparing 
to the group of patients with positive expression of CD10 (51.5 % versus 72.5 %, р=0.01). In the 
group of patients with negative expression of Bcl-6 there was worse OS comparing to the group of 
patients with positive expression of Bcl-6 (61.1 % versus 79.6 %, р=0.03) (Fig. 2).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b
Fig. 2. Survival of DLBCL patients depending on IHC markers expression:  
a – EFS of patients with positive (1, red line) and negative (0, black line) expression of CD10;  
b – OS of patients with positive (1, red line) and negative (0, black line) expression of Bcl-6 
An analysis of the association of treatment results of patients with DLBCL with different 
factor characteristics (27 clinical characteristics of patients, including IPI factors, IHC expression 
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of Bcl-2, MUM1, Bcl-6, CD10, CD30, С-MYC etc.) was performed. As a starting point, the like-
lihood of survival for more than 12 months was chosen. Outcome variable Y=0 for patients with 
OS>12 months (176 patients), Y=1 for patients with OS 12 months or less (57 patients).
The 27-factor linear neural network model for prediction survival less than 12 month was 
built with 79.3 % (95 % IU 58.5-83.0 %) of sensitivity and 80.1 % (95 % IU 73.4 % – 85.7 %) of 
specificity. 
As a result of selection of the minimum number of the most significant factors the method 
of genetic selection algorithm was used [1]. There were six characteristics for prognosing survival 
<12 months: negative IHC expression of Bcl-6 (X1), CD10 (X2), non-GCB molecular subtype (ac-
cording to algorithm Hans) (X3), gender (male) (X4), advanced Ann-Arbor stages (X5), >2extranodal 
involvement (X6). Based on this characteristics 6-factor linear prediction model (Lin_6) with 86.0 % 
(95 % CІ 74.2 % – 93.7 %) of sensitivity and 62.5 % (95 % CІ 54.9 % – 69.7 %) of specificity was built. 
In order to find out the possible nonlinear relationships of the distinguished factor charac-
teristics and the risk of low survival, in the third stage of the analysis, a six-factors nonlinear neural 
network prediction model (such as a multi-layered perceptron with one hidden layer) (MLP_6) with 
the same parameters was built. The sensitivity of the model is 63.2 % (95 % CІ 49.3 % – 75.6 %), 
specificity – 85.2 % (95 % CІ 79.1 % – 90.1 %). Fig. 3 shows the architecture of this model.
Fig. 3. Architecture of six-factor nonlinear neural network prediction model for prognosis of low 
survival. White triangles are the neurons of the input layer, the gray squares - the hidden layer 
neurons, the white square - the neuron of the initial layer of the network
The method of comparison of curves of operational characteristics of models was used 
for comparison of prognosis qualities of three constructed predicting models: Lin_27, Lin_6 and 
MLP_6 (Fig. 4).
Fig. 4. Curves of operational characteristics of prognosis qualities of three constructed  
predicting models
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According to this analysis of ROC-curves there were no differences between Lin_27 and 
MLP_6. 
To choose the optimal threshold, the decision was made based on minimizing the prediction 
error (minimizing the error of false negative + false positive results). At the same time, the same 
value of errors was chosen. When conducting an optimization, the threshold value Ycrit=0.527, 
while Y≤Ycrit in the model predicts the risk of low survival, otherwise the prognosis is favorable. 
Group of patients with positive and negative expression of IHC markers Bcl-2, Bcl-6, CD10, 
CD30, MUM1 та C-MYC were comparable in such characteristics as old age, advanced stages, ele-
vated LDH, more than two extranodal involvements, ECOG>2. There were more high risk patients 
according IPI in the group of patients with positive Bcl-2 expression (р=0.04).
There were statistically significant difference in EFS between the group of patients with 
negative and positive expression of CD10 (51.5 % versus 72.5 %, р=0.01) and in OS between the 
group of patients with negative and positive expression of Bcl-6 (61.1 % versus 79.6 %, р=0.03).
Six-factors nonlinear neural network prediction model (MLP_6) was built. The sensitiv-
ity of the model is 63.2 % (95 % CІ 49.3 % – 75.6 %), specificity – 85.2 % (95 % CІ 79.1 % – 
90.1 %). Prognostic factors include negative IHC expression of Bcl-6, CD10, non-GCB molecular 
subtype (according to algorithm Hans), gender (male), advanced Ann-Arbor stages, >2 extran-
odal involvement.
5. Discussion
Despite more numbers of high risk patients according IPI were in the group of patients with 
positive Bcl-2 expression, expression of this IHC marker did not have any influence on survival and 
did not show significant value during multivariable analysis. The results of study by Wilson W. H. 
and colleagues also demonstrated the absence of prognostic role of Bcl-2 expression.
Our analysis suggests association between negative IHC expression of CD10 and Bcl-6 and 
inferior outcome in patients with DLBCL.According to the Hans’ et al. and Berglund’s et al. data, 
positive expression of CD10 and Bcl6 also are associated with better survival. 
This suggestion was also confirm in multivariable analysis where six independent factors 
of poor survival were identified. Apart from 2 IPI factors (age, extranodal involvements) 1 new 
clinical factor (gender) and 3 biological tumor characteristics were identified. This combination of 
three new biological factors in our prognostic model was not described in the literature before and 
is valuable addition to the IPI for identifying poor prognosis patients with DLBCL.
6. Conclusion
1. IPI is a standard, but not perfect predictor of prognosis in patients with DLBCL and it 
includes only clinical patients’ characteristics. 
2. Our nonlinear neural network prediction model could improve prognostic role of IPI by 
adding of biological tumor characteristics (IHC expression of CD10, Bcl-6, molecular subtype by 
IHC algorithm). 
3. This prognostic model needs further confirmation in larger studies.
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